Valin Technologies

Company Overview

Snapshot

Founded in January 2010 by Marian Gorecki, PhD, Saul Mashaal, and Yehuda Zelig, Valin Technologies operates with 11–50 employees. The company is currently in the Pre-Funding stage, focusing on the research and development of biological therapeutics and biosimilars. In January 2017, Valin Technologies achieved a significant milestone with its work on Directed Evolution in the Treatment of Psoriasis.

Business overview

Valin Technologies is a biotechnology company specializing in the research and development of biological therapeutics and biosimilars. The company focuses on developing drugs for markets with unmet medical needs and high business potential. Its core competency spans the entire biopharmaceutical development value chain, from early discovery through process development, CMC, preclinical, and clinical development, up to regulatory approval. Valin Technologies operates R&D laboratories in Yavne and Israel, alongside a GMP mini-pilot plant and two biologic manufacturing facilities in China.

Company Intelligence Q&A

What is Valin Technologies' primary focus?

Valin Technologies primarily focuses on the research and development of biological therapeutics and biosimilars, targeting markets with unmet medical needs and significant business potential.

When was Valin Technologies founded and by whom?

Valin Technologies was founded in January 2010 by Marian Gorecki, PhD, Saul Mashaal, and Yehuda Zelig.

Where does Valin Technologies conduct its research and manufacturing?

Valin Technologies manages R&D laboratories in Yavne, Israel, and China, and operates a GMP mini-pilot plant and two biologic manufacturing facilities in China.

What is a key technological achievement for Valin Technologies?

In January 2017, Valin Technologies made progress in the field of Directed Evolution in the Treatment of Psoriasis, showcasing its expertise in pharmaceuticals and biotechnology.

What is the current product development stage for Valin Technologies?

Valin Technologies' product development is currently in the Clinical Trial stage, indicating active progression towards market readiness.